Phase 3 Readout~month

Phase 3 Topline: A Phase 3, Randomized, Open-Label Study to Investigate the Efficacy and Safety of ITK Inhibitor Soqu

Name: Phase 3 Topline: A Phase 3, Randomized, Open-Label Study to Investigate the Efficacy and Safety of ITK Inhibitor Soqu
Start: 2028-12-01

December 1, 2028

Company: Corvus Pharmaceuticals, Inc. (CRVS)
Drug: relapsed
Indication: Lymphoma, T-Cell; Angioimmunoblastic T-cell Lymphoma; Lymphoma, T-Cell, Peripheral

Track this catalyst and more

Get real-time alerts, AI-powered analysis, and full catalyst coverage.

Start Free Full Calendar

Phase 3 Topline: A Phase 3, Randomized, Open-Label Study to Investigate the Efficacy and Safety of ITK Inhibitor Soqu — CRVS Phase 3 Readout | BioSniper